These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 26523292)
21. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. Costa MR; Pollara J; Edwards RW; Seaman MS; Gorny MK; Montefiori DC; Liao HX; Ferrari G; Lu S; Wang S J Virol; 2016 Nov; 90(22):10362-10378. PubMed ID: 27630232 [TBL] [Abstract][Full Text] [Related]
22. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431 [TBL] [Abstract][Full Text] [Related]
32. Lessons from HIV-1 vaccine efficacy trials. Excler JL; Michael NL Curr Opin HIV AIDS; 2016 Nov; 11(6):607-613. PubMed ID: 27537673 [TBL] [Abstract][Full Text] [Related]
33. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response. Ahlers JD Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623 [TBL] [Abstract][Full Text] [Related]
34. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Wee EG; Ondondo B; Berglund P; Archer J; McMichael AJ; Baltimore D; Ter Meulen JH; Hanke T Mol Ther; 2017 Feb; 25(2):494-503. PubMed ID: 28153096 [TBL] [Abstract][Full Text] [Related]
35. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920 [TBL] [Abstract][Full Text] [Related]
36. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665 [TBL] [Abstract][Full Text] [Related]
37. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002 [TBL] [Abstract][Full Text] [Related]
38. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Malkevitch NV; Robert-Guroff M Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S105-17. PubMed ID: 15285710 [TBL] [Abstract][Full Text] [Related]
39. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses. Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605 [TBL] [Abstract][Full Text] [Related]
40. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]